Technology

Technology

HIGHFIELD_onelips_horizontal

At HighField, lipids are an integral part of the therapeutic

We create targeted treatments that recognize the complexities of people and disease

Our lead clinical development programs target cancer. A cancer therapeutic requires a multilayered approach. The tumor microenvironment (TME) plays a pivotal role in the behavior and development of solid tumors. As the tumor cells proliferate, they have diverse interactions with surrounding tissues. Our lipid-based therapeutics address the TME to stop tumor growth.

We are also developing lipid nanoparticles (LNP) containing RNA for gene therapy in treatment of autoimmune and metabolic diseases as well as genetic diseases. Our LNPs are different from others such as those used for COVID vaccines. They are tailored for stability, sustained circulation, minimum toxicity and efficacy with longer lasting RNA expression producing greater amounts of the therapeutic proteins.

The Highfield Advantage

Our immuno-oncology and LNP platforms are built upon our unique capability to optimize components of a lipid therapeutic system to specific disease tissue.

Combined with our proprietary system for producing lipid structures with very high quality and consistency, HighField can produce therapeutics with maximum efficacy and safety.

Beating cancer with lipid-based therapeutics

On one level, we design our lipids to maximize their inherent targeting properties towards rapidly growing tissue, like cancer tissue. On another level, we enhance the targeting by attaching antibodies to the lipids to form immunoliposomes.

Our immunoliposomes offer greater payload capacity and flexibility than standard target therapeutics like antibody-drug conjugates (ADCs). The size and nature of the lipid assembly, targeting antibodies, drug payload and disease addressed are components driving the design of our therapeutics.

HighField has developed an iterative, continuous production process for lipid manufacture. This novel approach greatly improves quality and consistency.

Treating chronic and genetic diseases with LNP gene therapies

We are creating LNPs containing RNA such as siRNA and mRNA for expression of therapeutic proteins to treat chronic diseases such as autoimmune and metabolic disorders. An LNP-RNA complex can also be used for treatment of genetic diseases. When a patient is missing an important gene or needs additional levels of a gene’s mRNA product, HighField’s LNP-mRNA complexes can correct the disease-causing deficiencies. Our LNP-RNA complexes can create a steady long-term production of the RNA protein products without immune response.